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Abstract
Background: Human polyomavirus JCV is the etiologic agent of progressive multifocal leukoencephalopathy (PML),
a fatal demyelinating disease characterized by lytic infection of glial cells in the central nervous system. PML is seen
primarily in immunosuppressed patients and is mainly classified as an AIDS-defining disease. In addition to
structural capsid proteins, JCV encodes multiple regulatory proteins, including T-antigen and agnoprotein, which
are required for functional lytic infection. Previous studies have suggested that molecular interaction between viral
proteins and host factors play an important role in reactivation of JCV and progression of the viral life cycle in glial
cells. Recently, serine/arginine rich splicing factor 1 (SRSF1), a cellular alternative splicing factor, was identified as a
strong negative regulator of JCV in glial cells. SRSF1 inhibits JCV gene expression and viral replication by directly
interacting with viral promoter sequences. Here, we have investigated possible impact of JCV regulatory proteins,
T-antigen and agnoprotein, on SRSF1-mediated suppression of JCV gene expression in glial cells.
Results: Reporter gene analysis has suggested that T-antigen rescues viral transcriptional suppression mediated by
SRSF1. Further analyses have revealed that T-antigen promotes viral gene expression by suppressing SRSF1 gene
transcription in glial cells. A subsequent ChIP analysis revealed that T-antigen associates with the promoter region
of SRSF1 to induce the transcriptional suppression.
Conclusions: These findings have revealed a molecular interplay between cellular SRSF1 and viral T-antigen in
controlling JCV gene expression, and may suggest a novel mechanism of JCV reactivation in patients who are at
risk of developing PML.
Introduction
JC virus (JCV) is a human polyomavirus and the etio-
logical agent of progressive multifocal leukoencephalo-
pathy (PML), a fatal demyelinating disease of the white
matter [1–3]. PML is primarily found in AIDS-patients,
with between 3 % and 5 % of patients developing PML
[4, 5]. However, PML has recently been diagnosed in
patients undergoing immunomodulatory therapy with
monoclonal antibodies against immune cells, such as
Natalizumab, Rituximab, and Efalizumab, which indi-
cates an immune component to the reactivation of the
virus from latent reservoirs [6–9]. JCV is a non-
enveloped polyomavirus with a genome comprised of
5 kb of double-stranded circular DNA with a bidirectional
non-coding control region separating the early and late
coding regions [10]. The early coding region of JCV
encodes regulatory proteins, T-antigen, small t-antigen,
and T’ splice variants expressed upon alternative splicing
of the primary viral transcript [11]. The late coding region
of JCV encodes the viral capsid proteins, VP1, VP2, and
VP3, which are required for the formation of the viral
capsid, as well as the small regulatory protein agnoprotein.
Previous studies have demonstrated that JCV under-
goes cell-type specific activation, primarily in glial cells,
which is proposed to be regulated at the transcriptional
level [12]. Cellular proteins, such as SRSF1, play a major
* Correspondence: isariyer@temple.edu
Department of Neuroscience, Center for Neurovirology, Temple University
Lewis Katz School of Medicine, 3500 North Broad Street, 7th Floor,
Philadelphia, PA 19140, USA
© 2015 Craigie et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Craigie et al. Virology Journal  (2015) 12:196 
DOI 10.1186/s12985-015-0426-x
role in controlling JCV infection in glial cells [10]. We
have recently identified alternative splicing factor SRSF1
as a negative regulator of JCV gene expression and repli-
cation in glial cells [10]. SRSF1 functions by targeting
the JCV promoter and strongly inhibits JCV early and
late gene transcription. Likewise, the down regulation of
SRSF1 in astrocytes increases levels of viral gene expres-
sion and replication [10]. SRSF1 is a strong negative
regulator of JCV gene expression as it suppresses both
early and late gene transcription in glial cells [10, 13,
14]. Moreover, SRSF1 interaction with the CR3 region of
JCV promoter sequences has been shown to be required
for the ability of SRSF1 to regulate JCV gene expression
and replication [14]. In order to proceed to a productive
replication cycle, JC virus has to initiate the transcription
of viral early and late genes by releasing the transcrip-
tional silencing caused by host factors, such as SRSF1.
While cellular factors hold a negative pressure on
viral gene expression in infected cells, viruses have
evolved and developed strategies to bypass host
defense mechanisms by utilizing mainly their regulatory
proteins [15–22]. Here we investigated possible role of
JCV regulatory proteins, T-antigen and agnoprotein, in
regulation of viral transcriptional suppression mediated by
SRSF1. Our results suggest that T-antigen but not agno-
protein is able to rescue and initiate viral transcription
suppressed by SRSF1. These results have revealed a novel
interaction between T-antigen and SRSF1 in controlling
JCV gene transcription and replication, which may suggest
a unique mechanism of JCV reactivation in patients who
are at risk of developing PML.
Results
Effect of JCV regulatory proteins, T-antigen and
agnoprotein, on SRSF1-mediated suppression of
JCV transcription
In order to investigate the role of JCV regulatory pro-
teins T-antigen and agnoprotein in SRSF1-mediated sup-
pression of JCV gene expression, primary human fetal
astrocytes (PHFA) were transiently transfected with a lu-
ciferase reporter construct in both early and late orienta-
tions (pLuc.JCV-Early or pLuc.JCV-Late). In addition to
transfection with the luciferase reporter construct, PHFA
cells were co-transfected with plasmids encoding SRSF1
(pCGT7-SRSF1), T-antigen (pCDNA3.1-T-ag), and agno-
protein (pCGT7-agno) in varying combinations. At 48 h
post transfections, JCV early and late transcription was
analyzed by luciferase reporter assay as described in ma-
terials and methods. Luciferase assay of JCV-early gene
transcription showed a strong suppression with SRSF1,
which was rescued by co-expression of T-antigen, as well
as a significant increase in transcription with the expres-
sion of T-antigen alone (Fig. 1a). However, there was no
observed effect of agnoprotein on transcriptional
suppression by SRSF1. Similarly, luciferase assay of JCV-
late gene transcription yielded strong suppression of
transcription with SRSF1, and a significant increase in
transcription with T-antigen. When compared with the
early gene transcription, SRSF1 possessed a much stronger
suppression of late gene transcription (compare panel A,
lane 3 with panel C, lane 3). Consistent with early gene
transcription, T-antigen was also able to rescue the
SRSF1-mediated transcriptional suppression of late pro-
moter (Fig. 1c). Western blot analysis of the whole cell
protein extracts were completed, demonstrating overex-
pression of SRSF1 and the expression of the viral proteins
that were transfected in parallel to luciferase assays
(Fig. 1b, d). These results suggest a novel role of viral T-
antigen in suppression of cellular SRSF1 in glial cells.
T-Antigen inhibits SRSF1 expression in glial cells
To determine possible impact of T-antigen on cellular ex-
pression of SRSF1, both primary human fetal astrocytes
(PHFA) and a human glioblastoma cell line (T98G) were
transiently transfected with an expression vector encoding
T-antigen in increasing concentrations. After 48 h post-
transfection, cells were harvested and the whole cell pro-
tein extracts were analyzed by Western blotting for the
detection of SRSF1 expression. As shown in Fig. 2a and b,
expression of T-antigen caused a significant reduction in
the basal expression levels of SRSF1 in PHFA cells in a
dose dependent manner. On the other hand, consistent
with primary glial cultures, expression of T-antigen also
caused a significant reduction in SRSF1 levels in T98G
cells (Fig. 2c and d). The early gene product small t anti-
gen was also expressed by alternative splicing of T-antigen
pre-mRNA and detected in the same immunoblots. These
results suggest that JCV T-antigen can target and down-
regulate the expression of cellular SRSF1.
T-Antigen targets SRSF1 promoter and inhibits
its transcription
In order investigate the molecular mechanism of T-
antigen-mediated suppression of SRSF1 expression in glial
cells, a luciferase assay reporting the transcriptional activ-
ity of the SRSF1 promoter was utilized. T98G cells were
transiently transfected with a luciferase reporter construct
consist of −1000 to +48 bp promoter region of SRSF1.
Along with luciferase reporter construct, cells were co-
transfected with plasmids encoding T-antigen or agnopro-
tein to determine the impact of these viral proteins on
SRSF1 transcription. Cells were also transfected with an
expression plasmid encoding green fluorescein protein
(GFP) to access the transfection efficiencies. After 48 h,
cells were harvested and processed for luciferase assay. It
was observed that T-antigen, but not agnoprotein, sup-
pressed the transcriptional activity of SRSF1 promoter
(Fig 3a and b). Similar to our previous experiments (Fig. 2),
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it was found that higher levels of T-antigen correspond to
a greater decrease in the transcriptional activity of SRSF1,
which accounts for the decreased expression of SRSF1 in
T-antigen expressing cells. To better understand the
events associated with T-antigen suppression of SRSF1
promoter activity, we designed a series of experiments to
assess the ability of T-antigen to bind to the SRSF1 pro-
moter sequences. T98G cells were transfected with ex-
pression plasmid encoding T-antigen, cross-linked and
possible interaction of T-antigen with SRSF1 promoter
was analyzed by ChIP assay using antibodies to T-antigen
as described in Materials and Methods. ChIP analysis of
the cells demonstrated the association of T-antigen with
SRSF1 promoter sequences (Fig. 3b).
Discussion
Viral life cycles within the body are a fight between the
ability of the host to recognize and quarantine or destroy
the viruses and the virus’s ability to avoid this detection
or avoid the mechanisms used to alter viral function.
Therefore, the interplay between viral regulatory pro-
teins and the host defense factors is a major regulator of
the viral life cycle. While cellular factors holds a negative
pressure on viral gene expression in infected cells, viruses
have evolved and developed strategies to bypass host
defense mechanisms by utilizing mainly their regulatory
proteins [15–22]. One example by which a viral protein
interacts with a host anti-viral protein is within the infec-
tion process of human cytomegalovirus (HCMV). When
Fig. 1 SRSF1 mediated suppression of JCV-early and -late gene transcription is complemented by T-Antigen. a. Luciferase assay showing the
effects on transcriptional activity of the JCV early promoter region by SRSF1, T-antigen, and agnoprotein. PHFA cells were co-transfected with
pLuc.JCV-Early and the listed expression plasmids. At 48 h post transfections, cell lysates were prepared and analyzed by luciferase reporter assay.
Luminescence was determined and normalized to protein concentrations. Standard deviations were calculated from three independent
experiments are presented as bar graph. Orientation of JCV Mad1 early promoter (GenBank: J02226.1) and firefly luciferase are schematized and
shown in the upper panel of the bar graph. b. Western blot analysis of whole cell extracts prepared in parallel to the samples in panel A.SRSF1
encoded by plasmid with a T7 tag is distinguished from endogenous SRSF1 levels. c. PHFA cells were transiently transfected with pLuc.JCV-Late
and listed plasmid combinations. At 48 h post transfections, cell lysates were prepared and analyzed by luciferase reporter assay. Luminescence
was determined and normalized to protein concentrations. Standard deviations were calculated from three independent experiments are
presented as bar graph. The orientation of JCV Mad1 late promoter (GenBank: J02226.1) and firefly luciferase are schematized and shown in the
upper panel of the bar graph. d. Western blot analysis of whole cell extracts prepared in parallel to the samples in panel c
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HCMV is detected by cells, an interferon gamma response
is induced, resulting in the expression of multiple antiviral
proteins, including the iron-sulfur cluster-binding antiviral
protein viperin [15–17]. During the infection cycle, pre-
expression of viperin results in inhibition of HCMV infec-
tion, however, the virus also is able to induce viperin ex-
pression independently of the IFN-dependent pathway
[17, 18]. Although viperin contains antiviral activity,
HCMV-induced viperin functions to disrupt cellular me-
tabolism through localization to the mitochondria in
infected cells, which results in enhancement of the HCMV
infection process [18–22]. HCMV encodes a viral
protein, viral mitochondrial inhibitor of apoptosis
(vMIA), which interacts with viperin during HCMV
infection, thus facilitating viral replication [18].
Similar to HCMV, JCV encodes viral regulatory pro-
teins which are required for the progression of the lytic
viral life cycle. We recently identified that cellular SRSF1
can overcome JCV reactivation by suppressing the ex-
pression of the viral genes [10, 13, 14]. Here, we investi-
gated the molecular interplay between SRSF1 and JCV
regulatory proteins T-antigen and agnoprotein in regula-
tion of the viral transcription. Our results demonstrate
that T-antigen is able to rescue the SRSF1-mediated
transcriptional suppression seen in both early and late
coding regions of the JCV genome. Likewise, it was
found that T-antigen alone significantly increased viral
transcription, however, a second viral regulatory protein,
agnoprotein, had no effect on JCV transcription. To de-
termine the mechanism behind T-antigen rescue of tran-
scriptional suppression mediated by SRSF1, the impact
of T-antigen expression on SRSF1 expression was ana-
lyzed. T-antigen expression decreased the expression of
SRSF1, thus allowing for increased viral transcription.
This step is hypothesized to be highly important within
the JCV infection process, as T-antigen acts as a tran-
scription factor for viral transcription and is able to
autoregulate the viral promoter to drive the required
viral processes for a productive infection cycle: in-
cluding DNA replication and transcription of the late
region allowing for agnoprotein and the capsid pro-
teins to be expressed [23, 24]. The observed suppres-
sion of SRSF1 levels within cells expressing T-antigen
was then demonstrated to be due to the T-antigen
interaction with the SRSF1 promoter region leading
to transcriptional inhibition.
Fig. 2 T-Antigen suppresses SRSF1 expression in glial cells. a. PHFA cells were transfected with increasing concentration of T-antigen expression
plasmid. After 48 h post-transfection, whole cell protein extracts were collected. Western blot analyses were performed to detect levels of SRSF1,
T-antigen, and small t antigen expressions. Grb2 served as a loading control. b. Bar graph representation of relative SRSF1 expression from panel
a. Quantification of the intensity of the bands of SRSF1 from panel a were normalized to Grb2 band intensities and used to calculate relative
expression. c. T98G cells were transfected with increasing concentration of T-antigen expression plasmid. After 48 h post-transfections, whole cell
protein extracts were collected. Western blot analyses were performed to detect levels of SRSF1, T-antigen, and small t antigen expressions.
GAPDH served as a loading control. d. Bar graph representation of relative SRSF1 expression from panel c. Quantification of the intensity of the
bands of SRSF1 were normalized to GAPDH band intensities and used to calculate relative SRSF1 expression levels. e. Whole cell protein lysates
from PHFA and T98G cells were prepared and analyzed by Western blotting for the detection of SRSF1 expression. GAPDH served as a loading
control. Band intensity of the bands of SRSF1 were quantified, normalized to GAPDH, and shown as bar graph
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Conclusion
In summary, our results demonstrate a novel role of
T-antigen in SRSF1-mediated suppression of JCV
gene expression and provide basis for the further in-
vestigation of the role of the molecular interplay be-
tween cellular SRSF1 and viral T-antigen in JCV
reactivation in glial cells leading to initiation of
productive viral life cycle in patients who are at risk
of developing PML.
Materials and methods
Cell lines and culture
The human glioblastoma multiforme cell line, T98G,
was obtained from American Type Culture Collection
Fig. 3 T-Antigen inhibits SRSF1 transcription through association with the promoter region. a. Effects of T-antigen and agnoprotein on SRSF1
transcription were tested by co-transfection studies. T98G cells were transiently transfected with pLuc.SRSF1(−1000) reporter plasmid and increasing
concentrations of T-antigen, agnoprotein, and GFP expression plasmids. After 48 h, cell extracts were collected and analyzed for luminescence and
normalized to protein concentrations. Relative luciferase activities were shown as bar graph. Standard deviations were calculated from
three independent experiments. A representative panel of images of GFP expression from live cells transfected with increasing concentrations of
pLEGFPC1 plasmid was also shown in the upper panel of the bar graph. b. Western blot analysis of whole cell extracts prepared in parallel to the
samples in panel a. c. T-antigen is associated with SRSF1 promoter region. T98G cells were either transfected with T-antigen or left untransfected and
proteins were cross-linked to DNA using formaldehyde, followed by ChIP analysis using antibody against T-antigen. Following immunoprecipitation,
beads were eluted and underwent subsequent DNA purification. Purified DNA was analyzed by PCR for the −1000 to + 49 promoter region of SRSF1.
In lane 2, the plasmid pLuc.SRSF1(−1000) was used as template and loaded as positive control. In lanes 5 and 6, samples from cells with and without
T-antigen were subjected to immunoprecipitation by anti-T-Antigen antibody (IP-T-ag). In lanes 3 and 4, samples from cells with or without T-antigen
expression were also subjected to immunoprecipitation by normal mouse serum (IP-NMS) as controls
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(ATCC) and grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 5 % heat-inactivated fetal bo-
vine serum (FBS) and penicillin/streptomycin (100 ug/ml).
T98G cells were maintained at 37 °C in a humidified
environment with 5 % CO2. Primary human fetal as-
trocytes were cultured from the fetal human brain of
a donor and provided by the Comprehensive
NeuroAIDS Core facility at Temple University and cul-
tured in Dulbecco’s Modified Eagle’s Medium/Nutrient
Mixture F-12 (DMEM/F-12) containing 10 % heat-
inactivated fetal bovine serum (FBS) penicillin/strepto-
mycin (100 μg/ml), GlutaMax (100 μg/mL) and insulin
(100 μg/mL). Cultured PHFA cells were maintained at
37 °C in a humidified atmosphere with 5 % CO2.
Plasmid constructs
The T-antigen gene was cloned into the eukaryotic ex-
pression vector pcDNA3.1 (+) at the EcoRI restriction
enzyme site and designated as pcDNA3.1-T-antigen pre-
viously [25]. pCGT7-SF2/ASF (SRSF1) expression plas-
mid was kindly provided by Javier F. Cáceres (Medical
Research Council Human Genetics Unit, Western
General Hospital, Edinburgh EH4 2XU, Scotland, United
Kingdom) and was described previously [26]. The
pCGT7-agno plasmid was described previously [27].
Briefly, agnoprotein coding sequence was cloned into
the eukaryotic expression plasmid pCGT7 at Xba1/
BamH1 restriction enzyme sites and designated as
pCGT7-agno. The luciferase reporter construct pLuc-
JCV-Early and pLuc-JCV-Late were made by blunt
end cloning of the full-length Mad-1 NCCR into the
SmaI site immediately upstream of the luciferase gene
in the plasmid pGL3 (Promega, Madison WI) and
described previously [28]. The luciferase reporter
plasmid pLuc-SRSF1 was made by cloning the −1000
to +49 promoter region of SRSF1 gene into pGL3
vector at BamH1 site.
Luciferase reporter assay
T98G cells were plated in 6-well tissue culture dishes
and transiently transfected with pLuc-JCV-Early, pLuc-
JCV-Late, or pLuc-SRSF1-1000 bp reporter plasmids
in the presence or absence of expression plasmids for
T-antigen and agnoprotein or pCDNA3.1 as control.
At 48 h post-transfection, cells were extracted and
lysed using reporter lysis buffer for the luciferase re-
porter system provided by the manufacturer Promega.
After cell lysis, luciferase activity of samples was de-
termined through the use of luciferase assay reagent
(LAR). The luciferase activities were then corrected
for protein concentrations and normalized to the
basal levels of transcription, allowing for determin-
ation of the fold changes.
Chromatin Immunoprecipitation Assay (ChIP)
T98G cells were transfected with pCDNA3.1-T-antigen.
At 48 h post-transfection, proteins were cross-linked to
DNA using formaldehyde at a final concentration of
1 %. After cross-linking, cells were lysed and subject to
sonication to fragment the chromatin. After sonication,
cells were incubated overnight with Protein G beads and
anti-T antigen antibody (pAb-416, Calbiochem) for
immunoprecipiation. After immunoprecipiation, the
beads were washed and bound proteins were eluted
using ChIP elution buffer (1 % SDS, 100 mM NaHCO3).
After elution, cross-linking was reversed by using 5 M
NaCl followed by Proteinase and RNase treatment. The
sample was then purified for DNA using phenol/chloro-
form extraction followed by ethanol precipitation.
Obtained DNA fragments were analyzed by PCR using
primers; SRSF1-Promoter-Forward (−1000 to +47): 5’-A
CCTTCCAAAGCTTTCCAGATTTCAG-3’ and SRSF1-
Promoter-Reverse (+47 to +27): 5’-ACCTTCCACTCG
AGGAAGGAAACAGC-3’. The PCR conditions were as
follows: denaturing at 95° for 30 s, annealing at 58 °C for
40 s, and extension at 72 °C for 65 s. The PCR products
were then resolved on a 1 % agarose gel.
Western blot
Whole cell protein extracts were washed with PBS and
lysed with TNN lysis buffer with protease inhibitors.
Purified protein extracts were then heated to 95 °C for
5 min and resolved through sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). After
resolution, the gel was transferred to a nitrocellulose
membrane (Whatman, Germany) for three hours at 250
mÅ at 4 °C in transfer buffer (25 mM Tris pH 7.4,
200 mM glycine, 20 % methanol). After transfer, mem-
branes were blocked for thirty minutes at room
temperature with 5 % non-fat dry milk in 1X phosphate-
buffered saline containing 0.1 % Tween-20 (PBST). After
blocking, membranes were washed and incubated with
primary antibodies at a 1:1000 dilution overnight at 4 °C.
After primary antibody incubation, membranes were
washed three times in PBST and incubated with second-
ary antibodies at a 1:5000 dilution at room temperature.
Following secondary antibody incubation, membranes
were visualized with the Odyssey CLx Imaging System
(LI-COR). Primary antibodies used were anti-T-antigen
(pAb-416, Calbiochem), anti-SRSF1 (ab12910, Abcam),
anti-agnoprotein (Pab7903, house raised), anti-β-Tubulin
(LI-COR), and anti-GAPDH (Cell Signaling Technol-
ogy). Secondary antibodies used were IRDye 800CW
goat anti-mouse (LI-COR) and IRDye 680RD goat
anti-rabbit (LI-COR).
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